Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group
study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and
venlafaxine ER 75 mg/day to 225 mg/day (flexible dose), compared to placebo. This study
consists of 2 week screening phase, 8 week treatment phase and 2 week tapering phase. The
follow-up visit will be evaluated after 2 weeks of last study medication dosing.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.